Replies to post #115175 on Biotech Values

[JJM760]

"The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!"

All of a sudden the market's perception of the value of a company is gospel?

I respectfully disagree with you (and others) belief that Ariad at a market cap of $735 million is over valued. Rida may not show efficacy in sarcoma (doubt it). I believe it will definitely show value in other indications in the near future. This story is 12 to 18 months away. If Pona turns out to be what I think it will, $735 will be a long way off in our rear view mirror. I have the time to wait.

I appreciate the opposing view point.